|
populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot
|
|
||
| Line 53: | Line 53: | ||
==External links== |
==External links== |
||
*[http://www.betaseron.com betaseron.com] |
*[http://www.betaseron.com betaseron.com] |
||
*[http://www.betaplus.ca BetaPlus Support Program] |
|||
*[http://www.www.bayerhealthcare.com Bayer HealthCare] |
|||
*[http://www.nationalmssociety.org National MS Society (USA)] |
|||
*[http://www.thisisms.com ThisIsMS] - an MS community website |
|||
*[http://www.zistdaru.ir Ziferon (Interferon beta-1b)] |
|||
{{Interferons}} |
{{Interferons}} |
||
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| MedlinePlus | a601151 |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| DrugBank | |
| KEGG | |
| ChEMBL | |
| ECHA InfoCard | 100.207.515  |
| Chemical and physical data | |
| Formula | C908H1408N246O253S6 |
| Molar mass | 20011.0 g/mol g·mol−1 |
Interferon beta-1b (tradenames Betaferon, Betaseron (North America), Extavia and ZIFERON) is a drug in the interferon family used to treat the relapsing-remitting and secondary-progressive forms of multiple sclerosis (MS). It is approved for use after the first MS event. It is administered by sub-cutaneous injection and has been shown to slow the advance of the affliction as well as reduce the frequency of attacks.
It is believed that interferon-beta based drugs achieve their beneficial effect on MS progress via their anti-inflammatory properties. Studies have also determined that interferon-beta improves the integrity of the blood-brain barrier (BBB)—which generally breaks down in MS patients, allowing increasing amounts of undesirable substances to reach the brain. This strengthening of the BBB may be a contributing factor to interferon-beta's beneficial effects. These studies were carried out in vitro, so it does not necessarily mean it works the same in people.
Patients taking Interferon beta-1b may develop neutralizing antibodies to the medication.[1] Reference link
Betaferon/Betaseron is marketed today by Bayer HealthCare. The originator was Schering AG (Berlex in North America), now part of Bayer HealthCare. Novartis has also introduced Extavia, a new brand of interferon beta-1b, in 2009.
In 2010 ZIFERON (a new brand for interferon beta-1b) has also been brought in by Zistdaru Danesh Ltd.
Closely related is interferon beta-1a, also indicated for MS, and with a very similar drug profile.
|
| |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| By family |
| ||||||||||||||||||||||||||||||||||||||||||
| By function/ cell |
| ||||||||||||||||||||||||||||||||||||||||||
|
| |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endogenous |
| ||||||||||||
| Exogenous |
| ||||||||||||
